These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10123838)

  • 41. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The health and cost effects of substituting home care for inpatient acute care: a review of the evidence.
    Soderstrom L; Tousignant P; Kaufman T
    CMAJ; 1999 Apr; 160(8):1151-5. PubMed ID: 10234345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outpatient parenteral antimicrobial therapy in osteoarticular infections in children.
    Maraqa NF; Gomez MM; Rathore MH
    J Pediatr Orthop; 2002; 22(4):506-10. PubMed ID: 12131449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center.
    Gauthier M; Chevalier I; Sterescu A; Bergeron S; Brunet S; Taddeo D
    Pediatrics; 2004 Oct; 114(4):e469-76. PubMed ID: 15466073
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Savings from outpatient antibiotic therapy for osteomyelitis. Economic analysis of a therapeutic strategy.
    Eisenberg JM; Kitz DS
    JAMA; 1986 Mar; 255(12):1584-8. PubMed ID: 3951094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of teicoplanin in gram-positive pulmonary infections.
    Sanduzzi A; Nani E; Sarno M; Vatrella A; Parrella R; Mattiello A
    J Chemother; 1991 Jan; 3 Suppl 1():224-6. PubMed ID: 12041771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A cost-effective approach to managing infectious disease.
    Wright RA
    Consultant; 1989 May; 29(5):143-6, 150, 155. PubMed ID: 10292917
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
    Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
    Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medical management of osteomyelitis: considerations for home antibiotic chemotherapy.
    Saravolatz LD; del Busto R; Markowitz N
    Clin Ther; 1988; 10(4):456-61. PubMed ID: 3079012
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outpatient parenteral antibiotic therapy. Management of serious infections. Part I: Medical, socioeconomic, and legal issues. Costs and benefits.
    Milkovich G
    Hosp Pract (Off Ed); 1993 Jun; 28 Suppl 1():39-43. PubMed ID: 8505397
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections.
    El Samad Y; Lanoix JP; Bennis Y; Diouf M; Saroufim C; Brunschweiler B; Rousseau F; Joseph C; Hamdad F; Ait Amer Meziane M; Routier S; Schmit JL
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6365-8. PubMed ID: 27458228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of outpatient parenteral antibiotics: a review of the literature.
    Balinsky W; Nesbitt S
    Am J Med; 1989 Sep; 87(3):301-5. PubMed ID: 2505615
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outpatient parenteral antibiotic therapy for bone and joint infections: an italian multicenter study.
    Esposito S; Leone S; Noviello S; Ianniello F; Fiore M; Russo M; Foti G; Carpentieri MS; Cellesi C; Zanelli G; Cellini A; Girmenia C; De Lalla F; Maiello A; Maio P; Marranconi F; Sabbatani S; Pantaleoni M; Ghinelli F; Soranzo ML; Vigano P; Re T; Viale P; Scudeller L; Scaglione F; Vullo V
    J Chemother; 2007 Aug; 19(4):417-22. PubMed ID: 17855186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of bone and joint infections utilizing a third-generation cephalosporin with an outpatient drug delivery device. HIAT Study Group.
    Mauceri AA
    Am J Med; 1994 Aug; 97(2A):14-22. PubMed ID: 8059796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term, once-weekly outpatient teicoplanin use for suppression of chronic prosthetic joint infection.
    Allen J; Adams K; Thompson F; Cullen L; Barlow G
    Int J Antimicrob Agents; 2013 Feb; 41(2):200-1. PubMed ID: 23182538
    [No Abstract]   [Full Text] [Related]  

  • 56. Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review.
    Krsak M; Morrisette T; Miller M; Molina K; Huang M; Damioli L; Pisney L; Wong M; Poeschla E
    Pharmacotherapy; 2020 May; 40(5):469-478. PubMed ID: 32239771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Teicoplanin in the treatment of bone and joint infections: An open study.
    LeFrock J; Ristuccia A
    J Infect Chemother; 1999 Mar; 5(1):32-39. PubMed ID: 11810487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biodegradable implantable teicoplanin beads for the treatment of bone infections.
    Yenice I; Caliş S; Kaş H; Ozalp M; Ekizoğlu M; Hincal A
    Int J Pharm; 2002 Aug; 242(1-2):271-5. PubMed ID: 12176262
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of insurance claims data to assess outpatient antimicrobial therapy for gram-positive infections.
    Carmeli Y; Mozaffari E
    Pharmacotherapy; 2002 Feb; 22(2 Pt 2):55S-62S. PubMed ID: 11837548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A cost-minimization study of cancer patients requiring a narcotic infusion in hospital and at home.
    Ferris FD; Wodinsky HB; Kerr IG; Sone M; Hume S; Coons C
    J Clin Epidemiol; 1991; 44(3):313-27. PubMed ID: 1705580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.